Moderna’s mRNA COVID-19 vaccine candidate has 94.5% efficacy
EMA starts rolling review, company to submit for USFDA EUA in coming weeks
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.